-
Mashup Score: 0
Some patients treated with prolonged courses of oral nirmatrelvir/ritonavir experienced long COVID symptom improvements, while others reported little to no changes in their symptoms.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 25Clinical trial shows 15-day Paxlovid regimen safe but adds no clear benefit for long COVID - 7 month(s) ago
In a clinical trial conducted by Stanford Medicine investigators and their colleagues, a 15-day course of Paxlovid—an antiviral drug combination targeting SARS-CoV-2, the virus that causes COVID-19—proved …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet-
Clinical trial shows 15-day #Paxlovid regimen safe but adds no clear benefit for long #COVID @sumedicine @JAMAInternalMed https://t.co/ZlpzQHTCju
-
-
Mashup Score: 207
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 Starting the antiviral drug nirmatrelvir-ritonavir (Paxlovid) 0 or 1 day after COVID-19 symptom onset halved 28-day all-cause death and hospitalization rates compared with waiting 2 or more days, University of Hong Kong researchers report in Nature Communications. The analysis was based on the electronic medical record data of all 87,070 high-risk adult outpatients and inpatients prescribed Paxlovid in Hong Kong from March 16, 2022, to
Source: www.cidrap.umn.eduCategories: General Medicine News, Infectious DiseaseTweet-
Early #Paxlovid for #COVID-19 halved death, hospitalization in new study Crude cumulative incidence of 28-day all-cause death or hospitalization was 5% for early initiators and 7% for delayed users. https://t.co/460rEcuUcL Photo: US Navy, Ryan M. Breeden / Flickr cc https://t.co/R5yaValkvo
-
-
Mashup Score: 201
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 Starting the antiviral drug nirmatrelvir-ritonavir (Paxlovid) 0 or 1 day after COVID-19 symptom onset halved 28-day all-cause death and hospitalization rates compared with waiting 2 or more days, University of Hong Kong researchers report in Nature Communications. The analysis was based on the electronic medical record data of all 87,070 high-risk adult outpatients and inpatients prescribed Paxlovid in Hong Kong from March 16, 2022, to
Source: www.cidrap.umn.eduCategories: General Medicine News, Infectious DiseaseTweet-
Early #Paxlovid for #COVID-19 halved death, hospitalization in new study Crude cumulative incidence of 28-day all-cause death or hospitalization was 5% for early initiators and 7% for delayed users. https://t.co/460rEcuUcL Photo: US Navy, Ryan M. Breeden / Flickr cc https://t.co/R5yaValkvo
-
-
Mashup Score: 201
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 Starting the antiviral drug nirmatrelvir-ritonavir (Paxlovid) 0 or 1 day after COVID-19 symptom onset halved 28-day all-cause death and hospitalization rates compared with waiting 2 or more days, University of Hong Kong researchers report in Nature Communications. The analysis was based on the electronic medical record data of all 87,070 high-risk adult outpatients and inpatients prescribed Paxlovid in Hong Kong from March 16, 2022, to
Source: www.cidrap.umn.eduCategories: General Medicine News, Infectious DiseaseTweet-
Early #Paxlovid for #COVID-19 halved death, hospitalization in new study Crude cumulative incidence of 28-day all-cause death or hospitalization was 5% for early initiators and 7% for delayed users. https://t.co/460rEcuUcL Photo: US Navy, Ryan M. Breeden / Flickr cc https://t.co/R5yaValkvo
-
An extended course of #Paxlovid may offer relief for certain patients with long #COVID, providing a potential option to address persistent symptoms and improve quality of life. Learn more: https://t.co/J3KZZswmiU